[强]_老虎社区_美港股上老虎

TSquare
2021-04-06

[强]

7 Healthcare Stocks to Buy to Prepare Your Portfolio For The Next Pandemic

While you might not want to hear it, given we’re still in the global grip of Covid-19, it must be sa

7 Healthcare Stocks to Buy to Prepare Your Portfolio For The Next Pandemic

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":343859849,"tweetId":"343859849","gmtCreate":1617705781181,"gmtModify":1631890448713,"author":{"id":3575584209294285,"idStr":"3575584209294285","authorId":3575584209294285,"authorIdStr":"3575584209294285","name":"TSquare","avatar":"https://static.tigerbbs.com/db7d2496d9cde731e866e67da91471fe","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>[强]&nbsp;</body></html>","htmlText":"<html><head></head><body>[强]&nbsp;</body></html>","text":"[强]","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/343859849","repostId":1186551401,"repostType":4,"repost":{"id":"1186551401","pubTimestamp":1617700731,"share":"https://www.laohu8.com/m/news/1186551401?lang=&edition=full","pubTime":"2021-04-06 17:18","market":"us","language":"en","title":"7 Healthcare Stocks to Buy to Prepare Your Portfolio For The Next Pandemic","url":"https://stock-news.laohu8.com/highlight/detail?id=1186551401","media":"investorplace","summary":"While you might not want to hear it, given we’re still in the global grip of Covid-19, it must be sa","content":"While you might not want to hear it, given we’re still in the global grip of Covid-19, it must be said:more pandemics are coming.\nHow much they will impact our day-to-day lives remains to be seen, but our current pandemic has shown investors the importance of diversified exposure to the healthcare sector. Positive vaccine news over the past several months has significantly improved the outlook for a return to normalcyand returned significant shareholder gains in many stocks. Over the past year, theDow Jones U.S. Health Care Indexis up over 36%.\nOur country spends about17% of its gross domestic product(GDP) on healthcare, one of the highest numbers worldwide. The industry umbrella covers major pharmas, smaller biotechnology firms, equipment manufacturers, telehealth businesses, healthcare providers, medical insurers and hospitals.\nHere are 7 healthcare stocks to buy to prepare your portfolio for the next pandemic:\n<ul>\n <li>Danaher(NYSE:DHR)</li>\n <li>ETFMG Treatments, Testing and Advancements ETF(NYSEARCA:GERM)</li>\n <li>Gilead Sciences(NASDAQ:GILD)</li>\n <li>Health Care Select Sector SPDR Fund(NYSEARCA:XLV)</li>\n <li>Hologic(NASDAQ:HOLX)</li>\n <li>Immunovant(NASDAQ:IMVT)</li>\n <li>Pfizer(NYSE:PFE)</li>\n</ul>\nGiven the devastating effects of the pandemic on personal lives and the economy, we can expect medical stocks to receive significant attention in the new decade as researchers and companies prepare for future pandemics.\nLOUIS NAVELLIER’S #1 STOCK FOR 2021\nHealthcare Stocks to Buy:Danaher (DHR)<img src=\"https://static.tigerbbs.com/dcc679e3fb5206fc509cfb46c378e087\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: madamF / Shutterstock.com\n52-week range:$119.60 — $248.86\nDividend yield:0.37%\nOur first choice for today is Danaher. The group manufactures scientific instruments and consumables in four segments: life sciences, diagnostics and environmental and applied solutions. The company has been growing both organically and through acquisitions.\nIn late 2019, Danaher separated its dental business through an initial public offering (IPO). That new company trades asEnvista(NYSE:NVST). Then in early 2020, it acquiredGeneral Electric’s(NYSE:GE) Biopharma segment, Cytiva. Along withFortive&nbsp;(NYSE:FTV), it is now expected to make a joint-bid for the British&nbsp;engineering groupRenishaw(OTCMKTS:RNSHY).\nDanaherreleased Q4 2020 financialsat the end of January. Revenue increased 39.0% YoY to $6.8 billion. Bottom line of $1.2 billion was an increase of 55.0% YoY. Non-GAAP adjusted diluted EPS for Q4 2020 were $2.08, a 62.5% YoY increase. Free cash flows from continuing operations were $5.4 billion.\nCEO Rainer M. Blair stated, “For the full year 2020, we achieved nearly 10% core revenue growth including Cytiva, strong margin expansion, and more than $5 billion of free cash flow.”\nOver the past year, DHR stock is up over 59%. Forward P/E and P/S ratios of29.50 and 7.13 indicate an overstretched valuation level. A potential decline toward the $210 level would improve the margin of safety. In the long-run, this company will benefit from higher demand for more medical and industrial products worldwide.\nLOUIS NAVELLIER’S #1 STOCK FOR 2021\nETFMG Treatments, Testing and Advancements ETF(GERM)<img src=\"https://static.tigerbbs.com/690d0f116893869dea8e073209cf14b4\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Shutterstock\n52-week range:$23.80 – $44.69\nDividend yield:0.17%\nExpense ratio:0.68% per year\nInvesting in the health sector via an exchange-traded fund (ETF) provides exposure to scientific development without needing to monitor the fast-paced pipeline of each company. This fund is made up of biopharma businesses developing cures and vaccines as well as diagnostic technology against infectious diseases.\nGERM began trading in June 2020, and assets under management stand at $55 million. It currently has 77 holdings and the top 10 names comprise close to 45% of the fund. Life sciences groupsLaboratory Corporation of America(NYSE:LH) andBio Rad Laboratories(NYSE:BIO), whose vaccines are currently being used worldwide,are among the leading names in the ETF, as well asModerna(NASDAQ:MRNA) andBioNTech(NASDAQ:BNTX).\nYear-to-date (YTD), the fund is up more than 10% and hit a record high in early February. In the past nine months, GERM’s short-term fortunes have ebbed and flowed with vaccine news headlines, especially as companies approached the final stages of clinical trials and received approvals by national authorities.\nThe thematic nature of this fund might appeal to investors who want to prepare their portfolios for the next pandemic.\nLOUIS NAVELLIER’S #1 STOCK FOR 2021\nGilead Sciences&nbsp;(GILD)<img src=\"https://static.tigerbbs.com/796d9670452315dd53f1b55075f40ea8\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Sundry Photography / Shutterstock.com\n52-week range:$56.56–$85.79\nDividend yield:4.35%\nBiopharma group Gilead Sciences develops therapies for HIV, cancer and viral hepatitis diseases. It has also played a central role in the Covid-19 pandemic, as Veklury, Gilead’s brand name remdesivir product, has treated a large number of hospitalized patients. The company has a market capitalization of more than $80 billion.\nGilead’sQ4 metricsshow that revenue increased by 26% YoY to $7.42 billion, catalyzed by Veklury sales. Non-GAAP net income almost doubled to $2.8 billion. Diluted EPS went up from $1.10 in Q4 2019 to $2.19 in fourth-quarter 2020. At the end of December 2020, Gilead had $7.9 billion on hand in cash and equivalents.\nManagement expects a gradual recovery in underlying market dynamics starting Q2 2021. The 2021 full year total revenue guidance currently stands in the range of $23.7 billion — $25.1 billion. In 2020, it was $24.4 billion.\nCEO Daniel O’Day said, “As we head into 2021, we have many additional opportunities to help patients, especially in oncology where Trodelvy, for example has the potential to treat a broad range of cancer types. These new opportunities, together with our continued leadership in antivirals put Gilead on a clear path to growth.”\nYet the company’s two HIV drugs recently&nbsp;lost exclusivity in the U.S. and sales are expected to continue to decline in the near future. It is quite common for pharma groups to see increased competition for their therapies (such as generics or biosimilars by other companies) as patents expire. Nonetheless, this fact has been a drag on the the GILD share price in the past year.\nGILD’s forward P/E and P/S ratios stand at 8.97 and 3.3, respectively. With its broad range of commercial therapies, robust pipeline, strong cash flow and juicy dividend yield, this company easily belongs in your portfolio.\nLOUIS NAVELLIER’S #1 STOCK FOR 2021\nHealth Care Select Sector SPDR Fund (XLV)<img src=\"https://static.tigerbbs.com/c3ac1b99cf1dcf4668eb27eaad6ae0ee\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Shutterstock\n52-Week range:$82.01 – $118.99\nDividend yield:1.78%\nExpense ratio:0.13 % per year\nOur next choice is another ETF, namely the Health Care Select Sector SPDR Fund. It gives access to businesses in the pharmaceuticals, biotechnology, healthcare equipment and services. Since its inception in December 1998, assets under management have grown to $24.3 billion.\nXLV currently has 63 holdings, and the top 10 names make up close to half of the fund. Among those leading names areJohnson &amp; Johnson(NYSE:JNJ),UnitedHealth(NYSE:UNH),Abbott Laboratories(NYSE:ABT), Pfizer,Merck(NYSE:MRK),&nbsp;Abbvie(NYSE:ABBV)andThermo Fisher Scientific(NYSE:TMO). This top-heavy fund invests in some of the larger caps in theS&amp;P 500 index. Many of these businesses have strong qualities including robust balance sheets, innovation and strong management.\nThe sector allocation is divided into Pharmaceuticals (28.27%), Healthcare Equipment &amp; Supplies (27.66%), Healthcare Providers &amp; Services (20.89%), Biotechnology (13.95%) and others.\nOver the past 12 months, XLV has returned over 34%. The fund’s trailing P/E and P/B ratios stand at 16.26 and 4.71, respectively. Given the recent volatility and profit-taking in broader markets, a decline toward or even below $110 is likely. Such a drop would provide a better entry point for buy-and-hold investors in this healthcare fund.\nLOUIS NAVELLIER’S #1 STOCK FOR 2021\nHologic(HOLX)<img src=\"https://static.tigerbbs.com/6bb121910093a91a7cac973f6982d1d7\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Shutterstock\n52-Week range:$28.71 – $85.00\nMassachusetts-based Hologic&nbsp; focuses on improving women’s health and well-being through early detection and treatment. The company operates in four segments including breast health, diagnostics, GYN surgical and skeletal health. It has been growing organically as well as through acquisitions.\nIn 2020, the company generated close to $3.8 billion in sales, with about half of revenue coming from diagnostics. This segment has seen an upsurge as its tests have been used extensively for Covid-19. Although we can expect diagnostics sales to decline in the coming months, I expect Hologic to put increased emphasis into this part of operations.\nHologic releasedFY2021 Q1results in late January. Revenue was $1.61 billion, up 89% YoY.Net income was $749.6 million, up 457% YoY.Non-GAAP diluted EPS was $2.86, an increase of 469% YoY.Cash and equivalents as of Dec. 26, 2020 were $868.7 million, up 227.7% YoY.\nCEO Steve MacMillan said in part:\n<blockquote>\n “Hologic had a strong start to fiscal 2021 across all our businesses and major geographies. Our Diagnostics division continued to deliver incredible performance by making a massive impact against COVID-19. Furthermore, our Breast Health and Surgical businesses continued to strengthen, with each returning to growth in the United States, Europe and Asia-Pacific.”\n</blockquote>\nHOLX stock’s forward P/E and P/S ratios are 8.58 and 4.17, respectively. Hologic’s focus has so far been mostly the U.S. But the new decade could easily see the company expand its operations overseas. With a market cap of about $19 billion, it has room for further growth.\nLOUIS NAVELLIER’S #1 STOCK FOR 2021\nImmunovant(IMVT)<img src=\"https://static.tigerbbs.com/844fce110f81f038db6eb743bf724d38\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Shutterstock\nNext on our list is Immunovant, a clinical-stage biopharmaceutical company that specializes in autoimmune diseases. The company became public in late 2019 following a reverse merger with Health Sciences Acquisitions Corporation, a special purpose acquisition company (SPAC). In a matter of weeks, IMVT shares saw a record high of $53.75, in part thanks to investors’ interest in the biopharma space in the year of the pandemic. But now, the shares are hovering at $15.\nAccording to the U.S.National Library of Medicine, “An autoimmune disorder occurs when the body’s immune system attacks and destroys healthy body tissue by mistake. There are more than 80 types of autoimmune disorders.” Antibodies play an important role in immune defense against pathogens, which cause diseases.\nFor instance, a recent article published inNaturehighlights, “The neutralizing antibodies that the immune system produces to disable the virus SARS-CoV-2 can last for at least nine months after infection, but not everyone makes them in detectable quantities.”\nPre-revenue company Immunovant has an investigational product candidate, IMVT-1401. It is intended as an injection to be applied under the skin for the treatment of autoimmune diseases caused by pathogenic IgG antibodies. However in early February, the companypausedclinical trials due to elevated levels of cholesterol. That development has put immense pressure on the share price.\nThe company releasedQ3 resultsresults in mid-February. Net loss for the quarter was $31.8 million, or 32 cents per common share. As the developments since February show, shares of biopharma companies can easily plunge on negative trial data news.\nImmunovant is clearly facing a major setback now. The stock could be appropriate for those investors who are able to stomach high risk for high returns in their portfolios.\nLOUIS NAVELLIER’S #1 STOCK FOR 2021\nPfizer (PFE)<img src=\"https://static.tigerbbs.com/7cb23d36e3d06dde4f91b54597b78acc\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: photobyphm / Shutterstock.com\n52-week range:$28.32 – $43.08\nDividend yield:4.3%\nPfizer is a leading pharmaceutical group with a market cap of $202 billion. In 2020, annual sales exceeded $40 billion. Pfizer and partner BioNTech developed the first vaccine against Covid-19. Although the company has become a household name thanks to this vaccine, it’s portfolio and pipeline extends to a wide range of therapies, such as oncology, inflammation, immunology, rare diseases and other vaccines.\nThe company’sQ4 financialsshowed revenue of $11.7 billion, 12% YoY growth. Non-GAAP bottom line improved by 15% YoY from $2,055 million in Q4 2019 to $2,366 million in Q4 2020. Diluted EPS&nbsp; was 36 cents. At the end of 2020, the company’s cash and equivalents stood at $1.8 billion.\nCFO Frank D’Amelio cited, “I am very pleased with how our company performed in 2020, and particularly in the fourth quarter, where we achieved double digit operational revenue growth driven by a wide range of products and geographies, including growth within all of our therapeutic areas.”\nIn 2021, Pfizer expects to post $59.4 billion to $61.4 billion in revenue. The midpoint of the guidance represents a 44% YoY growth. The increase in guidance was thanks to Covid-19 vaccine sales. The company’s forward P/Eand P/S ratios stand at 11.14 and 4.77 respectively. Its reliable cash flow as well as dividends should put the company on the radar of passive income seekers.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Healthcare Stocks to Buy to Prepare Your Portfolio For The Next Pandemic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Healthcare Stocks to Buy to Prepare Your Portfolio For The Next Pandemic\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-06 17:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/04/7-healthcare-stocks-to-buy-to-prepare-your-portfolio-for-the-next-pandemic/>investorplace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nWhile you might not want to hear it, given we’re still in the global grip of Covid-19, it must be said:more pandemics are coming.\nHow much they will impact our day-to-day lives remains to be seen, but...\n\n<a href=\"https://investorplace.com/2021/04/7-healthcare-stocks-to-buy-to-prepare-your-portfolio-for-the-next-pandemic/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMVT":"Immunovant, Inc.","XLV":"健康照护类股ETF-SPDR","GILD":"吉利德科学","HOLX":"豪洛捷","DHR":"丹纳赫","PFE":"辉瑞","GERM":"Amplify Treatments, Testing and Advancements ETF"},"source_url":"https://investorplace.com/2021/04/7-healthcare-stocks-to-buy-to-prepare-your-portfolio-for-the-next-pandemic/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186551401","content_text":"While you might not want to hear it, given we’re still in the global grip of Covid-19, it must be said:more pandemics are coming.\nHow much they will impact our day-to-day lives remains to be seen, but our current pandemic has shown investors the importance of diversified exposure to the healthcare sector. Positive vaccine news over the past several months has significantly improved the outlook for a return to normalcyand returned significant shareholder gains in many stocks. Over the past year, theDow Jones U.S. Health Care Indexis up over 36%.\nOur country spends about17% of its gross domestic product(GDP) on healthcare, one of the highest numbers worldwide. The industry umbrella covers major pharmas, smaller biotechnology firms, equipment manufacturers, telehealth businesses, healthcare providers, medical insurers and hospitals.\nHere are 7 healthcare stocks to buy to prepare your portfolio for the next pandemic:\n\nDanaher(NYSE:DHR)\nETFMG Treatments, Testing and Advancements ETF(NYSEARCA:GERM)\nGilead Sciences(NASDAQ:GILD)\nHealth Care Select Sector SPDR Fund(NYSEARCA:XLV)\nHologic(NASDAQ:HOLX)\nImmunovant(NASDAQ:IMVT)\nPfizer(NYSE:PFE)\n\nGiven the devastating effects of the pandemic on personal lives and the economy, we can expect medical stocks to receive significant attention in the new decade as researchers and companies prepare for future pandemics.\nLOUIS NAVELLIER’S #1 STOCK FOR 2021\nHealthcare Stocks to Buy:Danaher (DHR)Source: madamF / Shutterstock.com\n52-week range:$119.60 — $248.86\nDividend yield:0.37%\nOur first choice for today is Danaher. The group manufactures scientific instruments and consumables in four segments: life sciences, diagnostics and environmental and applied solutions. The company has been growing both organically and through acquisitions.\nIn late 2019, Danaher separated its dental business through an initial public offering (IPO). That new company trades asEnvista(NYSE:NVST). Then in early 2020, it acquiredGeneral Electric’s(NYSE:GE) Biopharma segment, Cytiva. Along withFortive (NYSE:FTV), it is now expected to make a joint-bid for the British engineering groupRenishaw(OTCMKTS:RNSHY).\nDanaherreleased Q4 2020 financialsat the end of January. Revenue increased 39.0% YoY to $6.8 billion. Bottom line of $1.2 billion was an increase of 55.0% YoY. Non-GAAP adjusted diluted EPS for Q4 2020 were $2.08, a 62.5% YoY increase. Free cash flows from continuing operations were $5.4 billion.\nCEO Rainer M. Blair stated, “For the full year 2020, we achieved nearly 10% core revenue growth including Cytiva, strong margin expansion, and more than $5 billion of free cash flow.”\nOver the past year, DHR stock is up over 59%. Forward P/E and P/S ratios of29.50 and 7.13 indicate an overstretched valuation level. A potential decline toward the $210 level would improve the margin of safety. In the long-run, this company will benefit from higher demand for more medical and industrial products worldwide.\nLOUIS NAVELLIER’S #1 STOCK FOR 2021\nETFMG Treatments, Testing and Advancements ETF(GERM)Source: Shutterstock\n52-week range:$23.80 – $44.69\nDividend yield:0.17%\nExpense ratio:0.68% per year\nInvesting in the health sector via an exchange-traded fund (ETF) provides exposure to scientific development without needing to monitor the fast-paced pipeline of each company. This fund is made up of biopharma businesses developing cures and vaccines as well as diagnostic technology against infectious diseases.\nGERM began trading in June 2020, and assets under management stand at $55 million. It currently has 77 holdings and the top 10 names comprise close to 45% of the fund. Life sciences groupsLaboratory Corporation of America(NYSE:LH) andBio Rad Laboratories(NYSE:BIO), whose vaccines are currently being used worldwide,are among the leading names in the ETF, as well asModerna(NASDAQ:MRNA) andBioNTech(NASDAQ:BNTX).\nYear-to-date (YTD), the fund is up more than 10% and hit a record high in early February. In the past nine months, GERM’s short-term fortunes have ebbed and flowed with vaccine news headlines, especially as companies approached the final stages of clinical trials and received approvals by national authorities.\nThe thematic nature of this fund might appeal to investors who want to prepare their portfolios for the next pandemic.\nLOUIS NAVELLIER’S #1 STOCK FOR 2021\nGilead Sciences (GILD)Source: Sundry Photography / Shutterstock.com\n52-week range:$56.56–$85.79\nDividend yield:4.35%\nBiopharma group Gilead Sciences develops therapies for HIV, cancer and viral hepatitis diseases. It has also played a central role in the Covid-19 pandemic, as Veklury, Gilead’s brand name remdesivir product, has treated a large number of hospitalized patients. The company has a market capitalization of more than $80 billion.\nGilead’sQ4 metricsshow that revenue increased by 26% YoY to $7.42 billion, catalyzed by Veklury sales. Non-GAAP net income almost doubled to $2.8 billion. Diluted EPS went up from $1.10 in Q4 2019 to $2.19 in fourth-quarter 2020. At the end of December 2020, Gilead had $7.9 billion on hand in cash and equivalents.\nManagement expects a gradual recovery in underlying market dynamics starting Q2 2021. The 2021 full year total revenue guidance currently stands in the range of $23.7 billion — $25.1 billion. In 2020, it was $24.4 billion.\nCEO Daniel O’Day said, “As we head into 2021, we have many additional opportunities to help patients, especially in oncology where Trodelvy, for example has the potential to treat a broad range of cancer types. These new opportunities, together with our continued leadership in antivirals put Gilead on a clear path to growth.”\nYet the company’s two HIV drugs recently lost exclusivity in the U.S. and sales are expected to continue to decline in the near future. It is quite common for pharma groups to see increased competition for their therapies (such as generics or biosimilars by other companies) as patents expire. Nonetheless, this fact has been a drag on the the GILD share price in the past year.\nGILD’s forward P/E and P/S ratios stand at 8.97 and 3.3, respectively. With its broad range of commercial therapies, robust pipeline, strong cash flow and juicy dividend yield, this company easily belongs in your portfolio.\nLOUIS NAVELLIER’S #1 STOCK FOR 2021\nHealth Care Select Sector SPDR Fund (XLV)Source: Shutterstock\n52-Week range:$82.01 – $118.99\nDividend yield:1.78%\nExpense ratio:0.13 % per year\nOur next choice is another ETF, namely the Health Care Select Sector SPDR Fund. It gives access to businesses in the pharmaceuticals, biotechnology, healthcare equipment and services. Since its inception in December 1998, assets under management have grown to $24.3 billion.\nXLV currently has 63 holdings, and the top 10 names make up close to half of the fund. Among those leading names areJohnson & Johnson(NYSE:JNJ),UnitedHealth(NYSE:UNH),Abbott Laboratories(NYSE:ABT), Pfizer,Merck(NYSE:MRK), Abbvie(NYSE:ABBV)andThermo Fisher Scientific(NYSE:TMO). This top-heavy fund invests in some of the larger caps in theS&P 500 index. Many of these businesses have strong qualities including robust balance sheets, innovation and strong management.\nThe sector allocation is divided into Pharmaceuticals (28.27%), Healthcare Equipment & Supplies (27.66%), Healthcare Providers & Services (20.89%), Biotechnology (13.95%) and others.\nOver the past 12 months, XLV has returned over 34%. The fund’s trailing P/E and P/B ratios stand at 16.26 and 4.71, respectively. Given the recent volatility and profit-taking in broader markets, a decline toward or even below $110 is likely. Such a drop would provide a better entry point for buy-and-hold investors in this healthcare fund.\nLOUIS NAVELLIER’S #1 STOCK FOR 2021\nHologic(HOLX)Source: Shutterstock\n52-Week range:$28.71 – $85.00\nMassachusetts-based Hologic  focuses on improving women’s health and well-being through early detection and treatment. The company operates in four segments including breast health, diagnostics, GYN surgical and skeletal health. It has been growing organically as well as through acquisitions.\nIn 2020, the company generated close to $3.8 billion in sales, with about half of revenue coming from diagnostics. This segment has seen an upsurge as its tests have been used extensively for Covid-19. Although we can expect diagnostics sales to decline in the coming months, I expect Hologic to put increased emphasis into this part of operations.\nHologic releasedFY2021 Q1results in late January. Revenue was $1.61 billion, up 89% YoY.Net income was $749.6 million, up 457% YoY.Non-GAAP diluted EPS was $2.86, an increase of 469% YoY.Cash and equivalents as of Dec. 26, 2020 were $868.7 million, up 227.7% YoY.\nCEO Steve MacMillan said in part:\n\n “Hologic had a strong start to fiscal 2021 across all our businesses and major geographies. Our Diagnostics division continued to deliver incredible performance by making a massive impact against COVID-19. Furthermore, our Breast Health and Surgical businesses continued to strengthen, with each returning to growth in the United States, Europe and Asia-Pacific.”\n\nHOLX stock’s forward P/E and P/S ratios are 8.58 and 4.17, respectively. Hologic’s focus has so far been mostly the U.S. But the new decade could easily see the company expand its operations overseas. With a market cap of about $19 billion, it has room for further growth.\nLOUIS NAVELLIER’S #1 STOCK FOR 2021\nImmunovant(IMVT)Source: Shutterstock\nNext on our list is Immunovant, a clinical-stage biopharmaceutical company that specializes in autoimmune diseases. The company became public in late 2019 following a reverse merger with Health Sciences Acquisitions Corporation, a special purpose acquisition company (SPAC). In a matter of weeks, IMVT shares saw a record high of $53.75, in part thanks to investors’ interest in the biopharma space in the year of the pandemic. But now, the shares are hovering at $15.\nAccording to the U.S.National Library of Medicine, “An autoimmune disorder occurs when the body’s immune system attacks and destroys healthy body tissue by mistake. There are more than 80 types of autoimmune disorders.” Antibodies play an important role in immune defense against pathogens, which cause diseases.\nFor instance, a recent article published inNaturehighlights, “The neutralizing antibodies that the immune system produces to disable the virus SARS-CoV-2 can last for at least nine months after infection, but not everyone makes them in detectable quantities.”\nPre-revenue company Immunovant has an investigational product candidate, IMVT-1401. It is intended as an injection to be applied under the skin for the treatment of autoimmune diseases caused by pathogenic IgG antibodies. However in early February, the companypausedclinical trials due to elevated levels of cholesterol. That development has put immense pressure on the share price.\nThe company releasedQ3 resultsresults in mid-February. Net loss for the quarter was $31.8 million, or 32 cents per common share. As the developments since February show, shares of biopharma companies can easily plunge on negative trial data news.\nImmunovant is clearly facing a major setback now. The stock could be appropriate for those investors who are able to stomach high risk for high returns in their portfolios.\nLOUIS NAVELLIER’S #1 STOCK FOR 2021\nPfizer (PFE)Source: photobyphm / Shutterstock.com\n52-week range:$28.32 – $43.08\nDividend yield:4.3%\nPfizer is a leading pharmaceutical group with a market cap of $202 billion. In 2020, annual sales exceeded $40 billion. Pfizer and partner BioNTech developed the first vaccine against Covid-19. Although the company has become a household name thanks to this vaccine, it’s portfolio and pipeline extends to a wide range of therapies, such as oncology, inflammation, immunology, rare diseases and other vaccines.\nThe company’sQ4 financialsshowed revenue of $11.7 billion, 12% YoY growth. Non-GAAP bottom line improved by 15% YoY from $2,055 million in Q4 2019 to $2,366 million in Q4 2020. Diluted EPS  was 36 cents. At the end of 2020, the company’s cash and equivalents stood at $1.8 billion.\nCFO Frank D’Amelio cited, “I am very pleased with how our company performed in 2020, and particularly in the fourth quarter, where we achieved double digit operational revenue growth driven by a wide range of products and geographies, including growth within all of our therapeutic areas.”\nIn 2021, Pfizer expects to post $59.4 billion to $61.4 billion in revenue. The midpoint of the guidance represents a 44% YoY growth. The increase in guidance was thanks to Covid-19 vaccine sales. The company’s forward P/Eand P/S ratios stand at 11.14 and 4.77 respectively. Its reliable cash flow as well as dividends should put the company on the radar of passive income seekers.","news_type":1},"isVote":1,"tweetType":1,"viewCount":416,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}